Vanda Pharmaceuticals (VNDA) Amortization - Intangibles (2010 - 2026)

Vanda Pharmaceuticals has reported Amortization - Intangibles for 17 years, with the latest figure at $2.0 million in Q1 2026.

• Quarterly Amortization - Intangibles rose 13.41% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 2.4% YoY) and the FY2025 annual result came in at $7.0 million, down 3.66% from the prior year.
• Amortization - Intangibles rose to $2.0 million in Q1 2026 per VNDA's latest filing, from $1.7 million in the prior quarter.
• Over five years, Amortization - Intangibles peaked at $2.0 million in Q1 2024 and troughed at $379000.0 in Q4 2022.
• A 5-year average of $1.2 million and a median of $1.7 million in 2025 frame the typical range for Amortization - Intangibles.
• The sharpest annual moves came in 2024 and 2025: Amortization - Intangibles surged 400.0% in 2024, then declined 12.4% in 2025.
• Over 5 years, Amortization - Intangibles stood at $379000.0 in 2022, then soared by 161.21% to $990000.0 in 2023, then jumped by 79.09% to $1.8 million in 2024, then fell by 3.72% to $1.7 million in 2025, then increased by 16.4% to $2.0 million in 2026.
• According to Business Quant data, Amortization - Intangibles over the past three periods registered $2.0 million, $1.7 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.